• ARID1A-Linked Melanoma Resistance Networks

  2026-10-08

  The reference study uses integrative multi-omics and network analysis to examine early drug responses in BRAF-driven melanoma, comparing a sensitive model with an ARID1A-knockout resistant derivative. Its findings connect persistent MAPK and JNK signaling, altered PRKD1 and JUN activity, receptor-kinase changes, and immune-relevant remodeling into a systems-level model of resistance.

• LY2228820 and p38 MAPK Research Evidence

  2026-10-08

  LY2228820 is a research tool for studying p38α/β MAPK signaling, inflammation, stress responses, and cancer biology. The supplied commercial description reports biochemical and preclinical activity, while the cited 2025 airway-stent study evaluated a different combination of anlotinib and silver nanoparticles. This overview separates those evidence streams and defines their applicability limits.

• LDN-193189: BMP Signaling Evidence and Limits

  2026-10-07

  LDN-193189 is a research small molecule used to investigate BMP type I receptor signaling, particularly ALK2 and ALK3. The supplied evidence supports a cautious interpretation: supplier-reported pathway activity provides mechanistic rationale, while the cited mammary-cell study offers important context on TGF-β, Sca-1, plasticity, and Smad signaling but does not, in the supplied material, establish a compound-specific LDN-193189 result.

• CUDC-907 Product Overview

  2026-10-07

  CUDC-907 (SKU A4097) is described by APExBIO as a dual PI3K and HDAC inhibitor for cancer-signaling research. No matched paper evidence was supplied, so this overview is limited to documented product identity and conceptual scope.

• Pexmetinib (ARRY-614): Beyond Dual-Target Inhibition

  2026-10-06

  Pexmetinib (ARRY-614) offers a useful model for interpreting dual-target kinase inhibition across inflammatory and hematologic research. This article distinguishes its p38 MAPK/Tie2 profile from a newer phosphatase-centered concept involving p38α dephosphorylation, clarifying what the evidence supports and where extrapolation should stop.

• Sorafenib Beyond Kinase Potency: Reading Angiogenesis Data

  2026-10-06

  Sorafenib, also known as BAY-43-9006, is more than a multikinase inhibitor: it is a useful cancer biology research tool for separating tumor-cell signaling from vascular effects. This article interprets its antiangiogenic evidence, compares assay contexts, and examines what recent VEGFR-2 inhibitor research can—and cannot—establish.

• Netarsudil: From ROCK Inhibition to siRNA Codelivery

  2026-10-05

  Netarsudil (AR-13324) is more than a ROCK pathway probe: emerging evidence positions it as both a cytoskeletal modulator and an ionizable small-molecule component for siRNA codelivery. This article separates established biology from formulation-specific findings and clarifies the boundaries of translational interpretation.

• LY2228820 and the Next Era of p38 MAPK Research

  2026-10-05

  LY2228820 offers a focused way to interrogate p38α/β signaling, while new structural work suggests that kinase inhibitors may also influence phosphatase access to activation-loop phosphorylation sites. This thought-leadership perspective separates established product-reported findings from emerging hypotheses and outlines a translational framework for inflammation and oncology research.

• IPA-3 in Pak1 and GCRV Entry Research

  2026-10-04

  IPA-3 is commonly described as a non-ATP-competitive Pak1 inhibitor, but the supplied evidence shows that its value depends strongly on biological context. In a 2018 grass carp reovirus study, IPA-3 did not inhibit viral entry or infection in CIK cells, while pharmacological and imaging evidence supported a clathrin-, dynamin-, and endosome-acidification-dependent entry model.

• Betulinic Acid, ERK, and Cyclophosphamide Liver Injury

  2026-10-03

  A 2025 Environmental Toxicology study identifies betulinic acid as a protective intervention in cyclophosphamide-induced liver injury in mice, linking reduced oxidative stress with NRF2 activation, ERK-MAPK suppression, improved mitochondrial dynamics, and lower apoptotic signaling. Its PD98059 perturbation arm strengthens the proposed ERK–mitochondrial apoptosis mechanism, while the animal-only design limits direct translation to clinical hepatoprotection.

• Busulfan Workflows for Germ-Cell Tracing

  2026-10-02

  Busulfan is a DNA alkylating agent that can create controlled cellular stress, senescence, and germ-cell depletion models. When paired with dual-recombinase lineage tracing, it helps distinguish loss of pre-existing germ cells from evidence of true ovarian regeneration.

• 17-AAG (Tanespimycin) Cancer Workflow

  2026-10-01

  Build reproducible HSP90 inhibition experiments with 17-AAG, from fresh-solution preparation and dose-response design to client-protein degradation and apoptosis readouts. The workflow also shows how a recent norovirus study can sharpen assay logic without implying antiviral activity for Tanespimycin.

• Thiazovivin ROCK Inhibitor Workflow Guide

  2026-10-01

  Thiazovivin is a ROCK inhibitor used to support fibroblast reprogramming for induced pluripotent stem cell generation and to improve human embryonic stem cell survival after trypsinization. This dossier-based guide covers preparation, controls, storage, and troubleshooting for in vitro stem cell research; it does not establish clinical use, diagnostic performance, or universal dosing.

• AZD8055: Practical mTOR Inhibitor Workflow

  2026-09-30

  AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling, cancer-cell proliferation, and selected metabolic endpoints. It is suited to preclinical pathway interrogation, but its aqueous insolubility, formulation requirements, and limited clinical benefit make it inappropriate as a substitute for clinical efficacy evidence.

• 12-O-tetradecanoyl phorbol-13-acetate (TPA)

  2026-09-30

  This scenario-driven guide explains how 12-O-tetradecanoyl phorbol-13-acetate (TPA), SKU N2060, can help researchers control ERK/MAPK pathway activation while interpreting viability, proliferation, and cytotoxicity data. It covers solvent compatibility, timing, controls, storage, vendor selection, and the limitations of translating pathway responses into cell-death conclusions.

8510 records 1/568 page Next 12345 下5页 Last page